Skip to main content

ADVERTISEMENT

Jonathan W Hodgson, MBA

Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease
Clinical Pathways GPS
03/16/2020
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Matthew Pakizegee, PharmD, MS
Jonathan W Hodgson, MBA
Chad McAuliffe
Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...
Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...
...
03/16/2020
Journal of Clinical Pathways